Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN: QVA149 Long-term Safety in COPD
NCT01120717Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2010
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing QVA149 with Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events, Serious Adverse Events or Death at Day 394. Started Apr 2010; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01120717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01120717.